A Single-centre, Open-label, Randomised, Single-dose, Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of Etavopivat in Healthy Participants
Latest Information Update: 21 Oct 2024
At a glance
- Drugs Etavopivat (Primary)
- Indications Sickle cell anaemia; Thalassaemia
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
Most Recent Events
- 17 Oct 2024 Status changed from recruiting to completed.
- 10 Jun 2024 Planned End Date changed from 15 Jul 2024 to 8 Jul 2024.
- 10 Jun 2024 Planned primary completion date changed from 15 Jul 2024 to 6 Jul 2024.